Using G-CSF to Boost Doxorubicin Treatment in Advanced Breast and Ovarian Cancer
Author Information
Author(s): M.H. Bronchud, A. Howell, D. Crowther, P. Hopwood, L. Souza, T.M. Dexter
Primary Institution: Cancer Research Campaign Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute
Hypothesis
Can granulocyte colony-stimulating factor (G-CSF) enhance the effectiveness of doxorubicin in patients with advanced breast and ovarian cancer?
Conclusion
The use of G-CSF allowed for higher doses of doxorubicin, resulting in an 80% response rate in patients with advanced breast cancer and improved symptoms.
Supporting Evidence
- G-CSF administration resulted in a return of the absolute neutrophil count to normal or above normal levels within 12-14 days.
- An overall response rate of 80% was observed in patients with advanced breast cancer treated with G-CSF.
- Patients reported a pronounced improvement of symptoms two months after doxorubicin-G-CSF therapy.
Takeaway
Doctors used a special medicine called G-CSF to help cancer patients get stronger doses of another medicine called doxorubicin, which helped many of them feel better.
Methodology
The study involved 21 patients with advanced breast and ovarian cancer who received varying doses of doxorubicin along with G-CSF to monitor treatment response and side effects.
Potential Biases
Potential bias due to the small sample size and lack of a randomized control group.
Limitations
The study was small and preliminary, limiting the ability to draw definitive conclusions.
Participant Demographics
Median age of participants was 53 years, with 19 having metastatic breast cancer and 2 with recurrent ovarian carcinoma.
Statistical Information
P-Value
0.086
Statistical Significance
p=0.086
Want to read the original?
Access the complete publication on the publisher's website